Funder: Vertex Pharmaceuticals

Due Dates: February 27, 2026: Beta thalassemia and sickle cell disease Investigator Sponsored Studies (ISS) RFP submission deadline

Funding Amounts: No strict cap; requests should reflect fair market value. Overhead not to exceed 35%. Vertex may fund up to 30% of an organization’s annual budget per year.

Summary: Supports independent medical education, patient advocacy, and investigator-initiated research in serious disease areas, including beta thalassemia and sickle cell disease.

Key Information: For beta thalassemia and sickle cell disease, proposals are only accepted during the current RFP window.